Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function

Journal of Clinical Investigation

Volumn 116, Issue 5, 2006, Pages 1391-1399

  Cheng, Yan ^a   Wang, Miao ^a   Yu, Ying ^a   Lawson, John ^a   Funk, Colin D ^b   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MICROSOMAL PROSTAGLANDIN E SYNTHASE 1; PROSTACYCLIN; PROSTAGLANDIN E; PROSTAGLANDIN G2; PROSTAGLANDIN INHIBITOR; PROSTAGLANDIN SYNTHASE; THROMBOXANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CATALYSIS; DRUG ACTIVITY; DRUG EFFECT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; THROMBOGENESIS;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 2; DINOPROSTONE; EPOPROSTENOL; FEMALE; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; THROMBOXANES;

EID: 33646415952     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27540     Document Type: Article

References (57)

1. Patrignani, P., et al. 1999. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J. Physiol. Pharmacol. 50:661-667.
2. Cheng, Y., et al. 2002. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 296:539-541.
3. FitzGerald, G.A. 2004. Coxibs and cardiovascular disease. N. Engl. J. Med. 351:1709-1711.
4. Grosser, T., Fries, S., and FitzGerald, G.A. 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116:4-15.
5. McAdam, B.F., et al. 1999. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U. S. A. 96:272-277.
6. Catella-Lawson, F., et al. 1999. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289:735-741.
7. Cullen, L., Kelly, L., Connor, S.O., and Fitzgerald, D.J. 1998. Selective cyclooxygenase-2 inhibition by nimesulide in man. J. Pharmacol. Exp. Ther. 287:578-582.
8. Murata, T., et al. 1997. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 388:678-682.
9. Trebino, C.E., et al. 2003. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. U. S. A. 100:9044-9049.
10. Egan, K.M., et al. 2005. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 111:334-342.
11. Penning, T.D., et al. 1997. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem. 40:1347-1365.
12. Riendeau, D., et al. 1997. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121:105-117.
13. Yu, Y., et al. 2005. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J. Clin. Invest. 115:986-995. doi:10.1172/JCI200523683.
14. Yu, Y., Fan, J., Chen, X.S., FitzGerald, G.A., and Funk, C.D. 2005. Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat. Med. In press.
15. Catella-Lawson, F., et al. 2001. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345:1809-1817.
16. Skuballa, W., Schillinger, E., Sturzebecher, C.S., and Vorbruggen, H. 1986. Synthesis of a new chemically and metabolically stable prostacyclin analogue with high and long-lasting oral activity. J. Med. Chem. 29:313-315.
17. FitzGerald, G.A. 2002. The choreography of cyclooxygenases in the kidney. J. Clin. Invest. 110:33-34. doi:10.1172/JCI200216044.
18. Brater, D.C. 2002. Anti-inflammatory agents and renal function. Semin. Arthritis Rheum. 32:33-42.
19. Cheng, H.F., and Harris, R.C. 2004. Cyclooxygenases, the kidney, and hypertension. Hypertension. 43:525-530.
20. FitzGerald, G.A. 2003. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2:879-890.
21. Aw, T.J., Haas, S.J., Liew, D., and Krum, H. 2005. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch. Intern. Med. 165:490-496.
22. Francois, H., et al. 2005. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2:201-207.
23. Pini, B., et al. 2005. Prostaglandin E synthases in zebrafish. Arterioscler. Thromb. Vasc. Biol. 25:315-320.
24. Schneider, A., et al. 2004. Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney. Kidney Int. 65:1205-1213.
25. Kennedy, C.R., et al. 1999. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat. Med. 5:217-220.
26. Watanabe, H., et al. 2005. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene. Circ. J. 69:124-126.
27. Fabre, J.E., et al. 2001. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J. Clin. Invest. 107:603-610.
28. Trebino, C.E., et al. 2005. Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. J. Biol. Chem. 280:16579-16585.
29. Furberg, C.D., Psaty, B.M., and FitzGerald, G.A. 2005. Parecoxib, valdecoxib, and cardiovascular risk [editorial]. Circulation. 111:249.
30. Crofford, L.J., et al. 2000. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum. 43:1891-1896.
31. Westgate, E.J., and FitzGerald, G.A. 2005. Pulmonary embolism in a woman taking oral contraceptives and valdecoxib. PLoS Med. 2:e197.
32. Farkouh, M.E., et al. 2004. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 364:675-684.
33. Yang, T., et al. 2005. Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. Am. J. Physiol. Renal Physiol. 288:F1125-F1132.
34. Seyberth, H.W., Sweetman, B.J., Frohlich, J.C., and Oates, J.A. 1976. Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins. 11:381-397.
35. Sullivan, J.C., Sasser, J.M., Pollock, D.M., and Pollock, J.S. 2005. Sexual dimorphism in renal production of prostanoids in spontaneously hypertensive rats. Hypertension. 45:406-411.
36. Smith, W.L., DeWitt, D.L., and Garavito, R.M. 2000. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69:145-182.
37. Marnett, L.J., Rowlinson, S.W., Goodwin, D.C., Kalgutkar, A.S., and Lanzo, C.A. 1999. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. 274:22903-22906.
38. Shimokawa, T., Kulmacz, R.J., DeWitt, D.L., and Smith, W.L. 1990. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J. Biol. Chem. 265:20073-20076.
39. Meyers, E.N., Lewandoski, M., and Martin, G.R. 1998. An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat. Genet. 18:136-141.
40. Loftin, C.D., Trivedi, D.B., and Langenbach, R. 2002. Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J. Clin. Invest. 110:549-557. doi:10.1172/JCI200214924.
41. Reese, J., et al. 2001. Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology. 142:3198-3206.
42. Sigthorsson, G., et al. 2002. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal antiinflammatory drug enteropathy in mice. Gastroenterology. 122:1913-1923.
43. Takano, T., et al. 2003. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis. J. Pharmacol. Exp. Ther. 305:240-249.
44. Tunctan, B., et al. 2006. Nitric oxide reverses endotoxin-induced inflammatory hyperalgesia via inhibition of prostacyclin production in mice. Pharmacol. Res. 53:177-192.
45. Shin, J.W., Hwang, K.S., Kim, Y.K., Leem, J.G., and Lee, C. 2006. Nonsteroidal antiinflammatory drugs suppress pain-related behaviors, but not referred hyperalgesia of visceral pain in mice. Anesth. Analg. 102:195-200.
46. Pratico, D., Cyrus, T., Li, H., and FitzGerald, G.A. 2000. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood. 96:3823-3826.
47. Bodary, P.F., Westrick, R.J., Wickenheiser, K.J., Shen, Y., and Eitzman, D.T. 2002. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA. 287:1706-1709.
48. Gresele, P., Corona, C., Alberti, P., and Nenci, G.G. 1990. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thromb. Haemost. 64:80-86.
49. Momi, S., et al. 2000. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur. J. Pharmacol. 397:177-185.
50. Gresele, P., et al. 1983. Dipyridamole inhibits platelet aggregation in whole blood. Thromb. Haemost. 50:852-856.
51. Booth, B.P., and Fung, H.L. 1998. Regulation of in vivo whole blood aggregation in rats by calcitonin gene related peptide. Can. J. Physiol. Pharmacol. 76:811-813.
52. Emery, J.D., et al. 1995. Whole-blood platelet aggregation predicts in vitro and in vivo primary hemostatic function in the elderly. Arterioscler. Thromb. Vasc. Biol. 15:748-753.
53. Tilley, S.L., et al. 1999. Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. J. Clin. Invest. 103:1539-1545.
54. Carlson, S.H., Oparil, S., Chen, Y.F., and Wyss, J.M. 2002. Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin- converting enzyme gene expression in transgenic mice. Hypertension. 39:214-218.
55. Carlson, S.H., and Wyss, J.M. 2000. Long-term telemetric recording of arterial pressure and heart rate in mice fed basal and high NaCl diets. Hypertension. 35:E1-E5.
56. Hui, Y., et al. 2004. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation. 110:3360-3366.
57. Rocca, B., et al. 2000. Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat. Med. 6:219-221.